Masao Nakata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masao Nakata has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Katsuhiko Shimizu
Department of General Thoracic Surgery, Kawasaki Medical School, Kurashiki, Okayama, Japan
11 shared publications - Ai Maeda
Department of General Thoracic Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki Okayama, 701-0192, Japan
9 shared publications Hideyuki Saeki
7 shared publications- Riki Okita
Department of Thoracic Surgery, National Hospital Organization Yamaguchi Ube Medical Center, Ube, Japan
7 shared publications - Takuro Yukawa
Department of General Thoracic Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki Okayama, 701-0192, Japan
7 shared publications Shigemitsu Takashima
5 shared publications
Latest Publications
- 1 January 2017
- Published by Japanese Association for Chest Surgery in The Journal of the Japanese Association for Chest Surgery
- Vol. 31 (7) , 836-841
Simultaneous multiple cancers discovered by FDG-PET/CT in patients with resectable non-small cell lung cancer
- 1 January 2017
- Published by Japanese Association for Chest Surgery in The Journal of the Japanese Association for Chest Surgery
- Vol. 31 (7) , 836-841
Simultaneous multiple cancers discovered by FDG-PET/CT in patients with resectable non-small cell lung cancer
- Open Access
- 29 June 2016
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 14 (1) , 1-4
Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report
Pneumatosis intestinalis (PI) is defined as the presence of gas in the bowel wall and is a relatively rare finding. PI has been associated with various pathological conditions and medications. Although several chemotherapeutic agents and molecular targeted therapy agents are reported to be associated with PI, there have been few reports describing the association between the anti-epidermal growth factor receptor agent gefitinib, a tyrosine kinase inhibitor (TKI), and PI. The present report describes a case of PI secondary to gefitinib therapy. An 80-year-old woman who had been diagnosed with recurrent lung adenocarcinoma presented with remarkable appetite loss, abdominal distension, and constipation after starting gefitinib therapy. A computed tomography (CT) scan of the abdomen revealed PI extending from the small intestine to the rectum. The patient was managed conservatively, and gefitinib therapy was discontinued. Subsequently, the symptoms improved and a follow-up abdominal X-ray showed a reduction in intramural air. After gefitinib was restarted, PI occurred three more times. Although PI is extremely rare, physicians should be aware of the risk of PI in patients undergoing gefitinib therapy.
- 29 June 2016
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 14 (1) , 1-4
Open AccessPneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report
Pneumatosis intestinalis (PI) is defined as the presence of gas in the bowel wall and is a relatively rare finding. PI has been associated with various pathological conditions and medications. Although several chemotherapeutic agents and molecular targeted therapy agents are reported to be associated with PI, there have been few reports describing the association between the anti-epidermal growth factor receptor agent gefitinib, a tyrosine kinase inhibitor (TKI), and PI. The present report describes a case of PI secondary to gefitinib therapy. An 80-year-old woman who had been diagnosed with recurrent lung adenocarcinoma presented with remarkable appetite loss, abdominal distension, and constipation after starting gefitinib therapy. A computed tomography (CT) scan of the abdomen revealed PI extending from the small intestine to the rectum. The patient was managed conservatively, and gefitinib therapy was discontinued. Subsequently, the symptoms improved and a follow-up abdominal X-ray showed a reduction in intramural air. After gefitinib was restarted, PI occurred three more times. Although PI is extremely rare, physicians should be aware of the risk of PI in patients undergoing gefitinib therapy.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 8521
A multi-center phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer
8521 Background: Previous studies have reported that adjuvant chemotherapy provides a survival benefit in patients with resected non-small cell lung cancer (NSCLC). In Japan, uracil-tegafur (UFT) has been used for patients with completely resected NSCLC. We conducted a phase III study of carboplatin/paclitaxel versus UFT as the adjuvant chemotherapy in resected NSCLC. Methods: The patients with pathological stage IB-IIIA NSCLC, who underwent complete resection, were randomized 1:1 to carboplatin (AUC 5) /paclitaxel (175 mg/m2) every 3 week for 4 cycles (A arm) or oral administration of UFT (250 mg/m2) daily for 2 years (B arm). The primary endpoint was overall survival (OS) and secondary endpoints were relapse-free survival (RFS) and toxicity. The sample size was calculated on the basis of previous reports of an approximately 45% 5-year survival rate for the stage I-IIIA patients treated with UFT and the A arm was assumed to be 60% 5-year survival rate. A total of 200 patients for each arm were required to detect a difference with an α error of .05 and power of 80% Results: Between November 2004 and November 2010, 402 patients from 40 Japanese institutions were randomized. The median follow-up period for survivor was 6.5 years. Median age of A and B arms combined was 67 years (range; 44-82). There were 260 men and 142 women enrolled. Two-hundred sixty five patients had adenocarcinoma, 101 had squamous cell carcinoma, and 36 had other histologies. Pathological stage was IB in 195 and II-III in 207 patients. The 5-year OS rate was 70% (95% confidential interval [CI] 63 to 76%) in the patients with A arm, versus 73% (95% CI 66 to 78%) in the patients with B arm, indicating no significant difference (P = 0.69). Regarding RFS, there was no significant difference between A and B arms (P = 0.50). Toxicities were well tolerated and there were no deaths related to the treatments. Among Grade 3/4 toxicities, hematological toxicity was major and significantly frequent in A arm compared with B arm (P< 0.01). Conclusions: As adjuvant chemotherapy, carboplatin/paclitaxel does not improve the survival among completely resected NSCLC patients with stage IB-IIIA compared with UFT. Clinical trial information: UMIN000000810.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 8521
A multi-center phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer
8521 Background: Previous studies have reported that adjuvant chemotherapy provides a survival benefit in patients with resected non-small cell lung cancer (NSCLC). In Japan, uracil-tegafur (UFT) has been used for patients with completely resected NSCLC. We conducted a phase III study of carboplatin/paclitaxel versus UFT as the adjuvant chemotherapy in resected NSCLC. Methods: The patients with pathological stage IB-IIIA NSCLC, who underwent complete resection, were randomized 1:1 to carboplatin (AUC 5) /paclitaxel (175 mg/m2) every 3 week for 4 cycles (A arm) or oral administration of UFT (250 mg/m2) daily for 2 years (B arm). The primary endpoint was overall survival (OS) and secondary endpoints were relapse-free survival (RFS) and toxicity. The sample size was calculated on the basis of previous reports of an approximately 45% 5-year survival rate for the stage I-IIIA patients treated with UFT and the A arm was assumed to be 60% 5-year survival rate. A total of 200 patients for each arm were required to detect a difference with an α error of .05 and power of 80% Results: Between November 2004 and November 2010, 402 patients from 40 Japanese institutions were randomized. The median follow-up period for survivor was 6.5 years. Median age of A and B arms combined was 67 years (range; 44-82). There were 260 men and 142 women enrolled. Two-hundred sixty five patients had adenocarcinoma, 101 had squamous cell carcinoma, and 36 had other histologies. Pathological stage was IB in 195 and II-III in 207 patients. The 5-year OS rate was 70% (95% confidential interval [CI] 63 to 76%) in the patients with A arm, versus 73% (95% CI 66 to 78%) in the patients with B arm, indicating no significant difference (P = 0.69). Regarding RFS, there was no significant difference between A and B arms (P = 0.50). Toxicities were well tolerated and there were no deaths related to the treatments. Among Grade 3/4 toxicities, hematological toxicity was major and significantly frequent in A arm compared with B arm (P< 0.01). Conclusions: As adjuvant chemotherapy, carboplatin/paclitaxel does not improve the survival among completely resected NSCLC patients with stage IB-IIIA compared with UFT. Clinical trial information: UMIN000000810.
- Open Access
- 30 September 2015
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 13 (1) , 291
Preoperative neutrophil/lymphocyte ratio and prognostic nutritional index predict survival in patients with non-small cell lung cancer
The immunological status, consisting of “inflammation status” and “nutritional condition,” is important for the survival of patients with various cancers, including non-small cell lung cancer (NSCLC). The neutrophil/lymphocyte ratio (NLR) reflects the inflammation status, and the prognostic nutritional index (PNI) reflects the immunological nutritional condition. In the present study, the correlation between the NLR and the PNI as well as the consistency and magnitude of the prognostic impact of the NLR and the PNI were investigated. We conducted a retrospective review of data from 334 patients who had undergone a curative resection for NSCLC. The NLR and the PNI were calculated, which was routinely performed before surgery. The correlations between the NLR and the PNI and survival were then evaluated. A clear inverse correlation was observed between the NLR and the PNI. The NLR was associated with sex, smoking history, the CEA level, tumor size, and vascular invasion. The PNI was associated with sex, age, smoking history, tumor size, histological type, tumor differentiation, and vascular invasion. Patients with NLR ≥2.5 had a significantly poorer survival outcome, and patients with PNI <50 had a significantly poorer survival outcome. A multivariate analysis demonstrated that age, nodal metastasis, tumor differentiation, NLR, and PNI were independent predictors of disease-free and overall survival. Our study demonstrated a significant inverse correlation between the NLR and the PNI, and a high NLR and a low PNI were significantly associated with a poor survival among patients who had undergone a complete resection for NSCLC.
- 30 September 2015
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 13 (1) , 291
Open AccessPreoperative neutrophil/lymphocyte ratio and prognostic nutritional index predict survival in patients with non-small cell lung cancer
The immunological status, consisting of “inflammation status” and “nutritional condition,” is important for the survival of patients with various cancers, including non-small cell lung cancer (NSCLC). The neutrophil/lymphocyte ratio (NLR) reflects the inflammation status, and the prognostic nutritional index (PNI) reflects the immunological nutritional condition. In the present study, the correlation between the NLR and the PNI as well as the consistency and magnitude of the prognostic impact of the NLR and the PNI were investigated. We conducted a retrospective review of data from 334 patients who had undergone a curative resection for NSCLC. The NLR and the PNI were calculated, which was routinely performed before surgery. The correlations between the NLR and the PNI and survival were then evaluated. A clear inverse correlation was observed between the NLR and the PNI. The NLR was associated with sex, smoking history, the CEA level, tumor size, and vascular invasion. The PNI was associated with sex, age, smoking history, tumor size, histological type, tumor differentiation, and vascular invasion. Patients with NLR ≥2.5 had a significantly poorer survival outcome, and patients with PNI <50 had a significantly poorer survival outcome. A multivariate analysis demonstrated that age, nodal metastasis, tumor differentiation, NLR, and PNI were independent predictors of disease-free and overall survival. Our study demonstrated a significant inverse correlation between the NLR and the PNI, and a high NLR and a low PNI were significantly associated with a poor survival among patients who had undergone a complete resection for NSCLC.
- Open Access
- 1 January 2015
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 13 (1) , 21
Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy
Adjuvant chemotherapy after the resection of stage IB-IIIA non-small cell lung cancer (NSCLC) is now the standard of care based on large-scale phase III trials and a meta-analysis. However, chemotherapy has plateaued in terms of its efficacy, and the search for treatment prediction biomarkers is imperative for the further identification of treatable subgroups. Therefore, we investigated the significance of cyclooxygenase-2 (Cox-2) expression and the applicability of a Cox-2 inhibitor in patients who had received adjuvant chemotherapy. We conducted a retrospective review of data from 97 patients who had received adjuvant chemotherapy. The adjuvant chemotherapy consisted of an oral tegafur agent (OT) or platinum-based chemotherapy (PB). The criteria for regimen selection were based on a discussion among the cancer board and enrollment in a clinical trial. Immunohistochemical staining (IHC) for Cox-2 was performed, and the correlation between Cox-2 expression and disease-free survival (DFS) was evaluated. IHC showed that 56 cases (57.7%) were positive for Cox-2. The rate of Cox-2 expression was similar for the PB and OT groups. Among the patients who received PB, the DFS of the patients with Cox-2 expression was significantly poorer than that of the patients without Cox-2 expression (P = 0.017), but there was no significant difference among the patients who received OT (P = 0.617). In a multivariate analysis, Cox-2 expression and lymph node metastasis were independent predictors of DFS among patients who received PB. Cox-2 expression was a powerful predictor of DFS among patients who received PB as an adjuvant chemotherapy. Further study investigating the use of a Cox-2 inhibitor for adjuvant chemotherapy is needed.
- 1 January 2015
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 13 (1) , 21
Open AccessCyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy
Adjuvant chemotherapy after the resection of stage IB-IIIA non-small cell lung cancer (NSCLC) is now the standard of care based on large-scale phase III trials and a meta-analysis. However, chemotherapy has plateaued in terms of its efficacy, and the search for treatment prediction biomarkers is imperative for the further identification of treatable subgroups. Therefore, we investigated the significance of cyclooxygenase-2 (Cox-2) expression and the applicability of a Cox-2 inhibitor in patients who had received adjuvant chemotherapy. We conducted a retrospective review of data from 97 patients who had received adjuvant chemotherapy. The adjuvant chemotherapy consisted of an oral tegafur agent (OT) or platinum-based chemotherapy (PB). The criteria for regimen selection were based on a discussion among the cancer board and enrollment in a clinical trial. Immunohistochemical staining (IHC) for Cox-2 was performed, and the correlation between Cox-2 expression and disease-free survival (DFS) was evaluated. IHC showed that 56 cases (57.7%) were positive for Cox-2. The rate of Cox-2 expression was similar for the PB and OT groups. Among the patients who received PB, the DFS of the patients with Cox-2 expression was significantly poorer than that of the patients without Cox-2 expression (P = 0.017), but there was no significant difference among the patients who received OT (P = 0.617). In a multivariate analysis, Cox-2 expression and lymph node metastasis were independent predictors of DFS among patients who received PB. Cox-2 expression was a powerful predictor of DFS among patients who received PB as an adjuvant chemotherapy. Further study investigating the use of a Cox-2 inhibitor for adjuvant chemotherapy is needed.
- Open Access
- 29 May 2014
- Published by Springer Nature in Diagnostic Pathology
- Vol. 9 (1) , 103
Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between "squamous" and "non-squamous" cell carcinoma
Non-small cell lung cancers (NSCLCs) are frequently heterogeneous and in approximately 70% of cases, NSCLCs are diagnosed and staged by small biopsies or cytology rather than by examination of surgically resected specimens. Thus, in most patients, the diagnosis is established based on examination of preoperative specimens alone. Recently, classification of NSCLC into pathologic subtypes has been shown to be important for selecting the appropriate systemic therapy, from both the point of view of treatment efficacy and prevention of toxicity.
- 29 May 2014
- Published by Springer Nature in Diagnostic Pathology
- Vol. 9 (1) , 103
Open AccessHistological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between "squamous" and "non-squamous" cell carcinoma
Non-small cell lung cancers (NSCLCs) are frequently heterogeneous and in approximately 70% of cases, NSCLCs are diagnosed and staged by small biopsies or cytology rather than by examination of surgically resected specimens. Thus, in most patients, the diagnosis is established based on examination of preoperative specimens alone. Recently, classification of NSCLC into pathologic subtypes has been shown to be important for selecting the appropriate systemic therapy, from both the point of view of treatment efficacy and prevention of toxicity.
- Open Access
- 1 January 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 343
Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma
The maximal standardized uptake value (SUVmax) on fluorodeoxyglucose-positron emission tomography (FDG-PET) for primary tumors is correlated with clinicopathological and prognostic factors in patients with non-small cell lung cancer. However, previous investigations have discussed the role of SUVmax without distinguishing among the histological subtypes of lung cancer. Herein, we investigated the correlations among the SUVmax on FDG-PET, clinicopathological or prognostic factors, and the expression of tumor angiogenic biomarkers according to histological subtypes. We conducted a retrospective review of data from 52 patients with invasive adenocarcinoma (ADC) and 32 patients with squamous cell carcinoma (SQC) measuring less than 3 cm in diameter. Immunohistochemical staining for cyclooxygenase-2 (Cox-2), Ki-67, and vascular endothelial growth factor, which might influence cancer progression, was performed and the correlations between the expressions of these biomarkers and the SUVmax were evaluated. Among ADC patients, a statistically significant correlation was observed between the SUVmax and the major clinicopathological factors; among SQC patients, however, no statistically significant association was observed. The disease-free survival (DFS) period of the ADC patients with a high SUVmax was significantly poorer than that of the patients with a low SUVmax, but the DFS of the SQC patients with a high SUVmax was not significantly poorer. In a multivariate analysis, the pathological stage and the SUVmax were independent prognostic factors of the DFS among the ADC patients. Among the SQC patients, however, only Cox-2 expression was an independent prognostic factor of DFS. Some clear differences in prognostic values of the SUVmax on FDG-PET and Cox-2 expression exist between patients with ADC and those with SQC. Based on these relationships between the SUVmax and clinicopathological or biological factors that influence cancer progression, the importance of the SUVmax appears to be quite different for patients with ADC and those with SQC.
- 1 January 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 343
Open AccessDifference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma
The maximal standardized uptake value (SUVmax) on fluorodeoxyglucose-positron emission tomography (FDG-PET) for primary tumors is correlated with clinicopathological and prognostic factors in patients with non-small cell lung cancer. However, previous investigations have discussed the role of SUVmax without distinguishing among the histological subtypes of lung cancer. Herein, we investigated the correlations among the SUVmax on FDG-PET, clinicopathological or prognostic factors, and the expression of tumor angiogenic biomarkers according to histological subtypes. We conducted a retrospective review of data from 52 patients with invasive adenocarcinoma (ADC) and 32 patients with squamous cell carcinoma (SQC) measuring less than 3 cm in diameter. Immunohistochemical staining for cyclooxygenase-2 (Cox-2), Ki-67, and vascular endothelial growth factor, which might influence cancer progression, was performed and the correlations between the expressions of these biomarkers and the SUVmax were evaluated. Among ADC patients, a statistically significant correlation was observed between the SUVmax and the major clinicopathological factors; among SQC patients, however, no statistically significant association was observed. The disease-free survival (DFS) period of the ADC patients with a high SUVmax was significantly poorer than that of the patients with a low SUVmax, but the DFS of the SQC patients with a high SUVmax was not significantly poorer. In a multivariate analysis, the pathological stage and the SUVmax were independent prognostic factors of the DFS among the ADC patients. Among the SQC patients, however, only Cox-2 expression was an independent prognostic factor of DFS. Some clear differences in prognostic values of the SUVmax on FDG-PET and Cox-2 expression exist between patients with ADC and those with SQC. Based on these relationships between the SUVmax and clinicopathological or biological factors that influence cancer progression, the importance of the SUVmax appears to be quite different for patients with ADC and those with SQC.
- 1 October 2012
- Vol. 39 (10) , 1579-81
[Growing teratoma syndrome of the lung secondary to non-seminomatous germ cell tumor of the testis-a case report].
We report a rare case of growing teratoma syndrome(GTS). The patient was a 37-year-old man diagnosed as having a mixed germ cell tumor of the right testis. After resection of the right testis, the patient developed multiple lung metastases and chemotherapy was administered. However, in spite of the normalization of the serum AFP level, the lung metastases continued to increase in size. The lung metastases were successfully resected and pathological examination revealed the diagnosis of a mature teratoma. GTS is defined as an enlarging tumor mass during or after chemotherapy in the case of germ cell tumors, with normalization of the serum AFP. Total surgical resection of the mass yielded a good result. Recognition of this syndrome is important for successful treatment.
- 1 October 2012
- Vol. 39 (10) , 1579-81
[Growing teratoma syndrome of the lung secondary to non-seminomatous germ cell tumor of the testis-a case report].
We report a rare case of growing teratoma syndrome(GTS). The patient was a 37-year-old man diagnosed as having a mixed germ cell tumor of the right testis. After resection of the right testis, the patient developed multiple lung metastases and chemotherapy was administered. However, in spite of the normalization of the serum AFP level, the lung metastases continued to increase in size. The lung metastases were successfully resected and pathological examination revealed the diagnosis of a mature teratoma. GTS is defined as an enlarging tumor mass during or after chemotherapy in the case of germ cell tumors, with normalization of the serum AFP. Total surgical resection of the mass yielded a good result. Recognition of this syndrome is important for successful treatment.
- Open Access
- 11 July 2012
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 10 (1) , 141
Membrane-bound estrogen receptor-α expression and epidermal growth factor receptor mutation are associated with a poor prognosis in lung adenocarcinoma patients
The purpose of this study is to clarify the correlations between the expression of membrane-bound estrogen receptor-α (mERα) and epidermal growth factor receptor (EGFR) mutation and clinicopathological factors, especially in relation to the prognosis, in patients with lung adenocarcinoma.
- 11 July 2012
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 10 (1) , 141
Open AccessMembrane-bound estrogen receptor-α expression and epidermal growth factor receptor mutation are associated with a poor prognosis in lung adenocarcinoma patients
The purpose of this study is to clarify the correlations between the expression of membrane-bound estrogen receptor-α (mERα) and epidermal growth factor receptor (EGFR) mutation and clinicopathological factors, especially in relation to the prognosis, in patients with lung adenocarcinoma.
- 31 December 2010
- Published by Elsevier in Lung Cancer
- Vol. 70 (3) , 329-334
Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma
- 31 December 2010
- Published by Elsevier in Lung Cancer
- Vol. 70 (3) , 329-334
Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma